Harnessing multiple mechanisms of action to target Nectin-4 as anti-tumor therapeutics.

被引：0
|
作者：
Pei, Yi [1 ]
Pohl, Thomas [1 ]
Hassan, Ahmed [1 ]
Przybyla, Anna [1 ]
Yu, Raymond [1 ]
Lu, Huarui [1 ]
Tang, Fangqiang [1 ]
Chen, Kevin [1 ]
Jin, Wei [1 ]
Dominguez, Krizia [1 ]
Huang, Haichun [1 ]
Lei, Ming [1 ]
Liu, Zhong [1 ]
Li, Han [1 ]
机构：
[1] NovaRock Biotherapeut, Ewing, NJ USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
920
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
    Bouleftour, Wafa
    Sargos, Paul
    Magne, Nicolas
    CURRENT ONCOLOGY REPORTS, 2023, 25 (03) : 181 - 188
  • [2] Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
    Wafa Bouleftour
    Paul Sargos
    Nicolas Magne
    Current Oncology Reports, 2023, 25 : 181 - 188
  • [3] Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry
    Coricor, George
    McFarland, Jesse M.
    Srinivasan, Sangeetha
    Wagner, Stefanie
    Yee, Nathan
    Tri-Hung Nguyen
    Oneto, Jose M. Mejia
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    SEMINARS IN IMMUNOLOGY, 2016, 28 (03) : 309 - 316
  • [5] MECHANISMS INVOLVED IN THE ANTI-TUMOR ACTION OF ARGININE
    RETTURA, G
    LEVENSON, SM
    SEIFTER, E
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1980, 180 (AUG): : 130 - BIOL
  • [6] A NECTIN-4 TARGETED TLR9 AGONIST ANTIBODY CONJUGATE INDUCES ROBUST IMMUNE CELL ACTIVATION AND ANTI-TUMOR RESPONSES
    Chen, Amy
    Li, Min
    Bonacorsi, Maja
    Sangalang, Emma
    Fontaine, Danielle
    Harrabi, Ons
    An, Mingrui
    Chou, Tiffany
    Doyle, Laura
    Sim, Janet
    Han, Bora
    Wan, Hong
    Kuo, Tracy
    Costa, Maria Jose
    Strop, Pavel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1205 - A1205
  • [7] Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle®tumor-targeted immune cell agonist (TICA™).
    Hurov, Kristen
    Lahdenranta, Johanna
    Upadhyaya, Punit
    Kanakia, Drasti
    Repash, Elizabeth
    You, Fanglei
    Ma, Jun
    Haines, Eric
    Cohen, Heather
    McDonnell, Kevin
    Brandish, Philip E.
    Jeffrey, Phil
    Keen, Nicholas
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Multiple mechanisms of salidroside on anti-tumor effects
    Wang, X-P
    Yuan, D-Y
    Tian, Y.
    Li, W-H
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (17) : 5349 - 5354
  • [9] Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers
    Liu, Bernard A.
    Olson, Devra
    Snead, Katie
    Gosink, John
    Tenn, Elena-Marie
    Zaval, Margo
    Cao, Anthony
    Sahetya, Disha
    Nesterova, Albina
    Hensley, Kelly
    Cochran, Julia
    Gardai, Shyra
    Lewis, Timothy S.
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Nectin-4 cell-surface oncoprotein in serum and tumor issue as a diagnostic and therapeutic target for lung cancer
    Daigo, Yataro
    Takano, Atsushi
    Tsuchiya, Eiju
    Nakamura, Yusuke
    CANCER RESEARCH, 2010, 70
12345